Pancreatic Cancer Research

ResearcherFondazione IRCCS Istituto Nazionale dei TumoriActive in the last 2 years

Monica Niger

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-9055-5338; OpenAlex author ID A5030318941. Sources: OpenAlex.

Their work

Papers
15 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
75
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 2 papers · 2022: none · 2023: 4 papers · 2024: 2 papers · 2025: 3 papers · 2026: 3 papers

Papers 15

  1. Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond. Co-author DOI 10.1007/s11523-026-01236-x↗
  2. Impact of diabetes mellitus on treatment efficacy in patients with advanced pancreatic cancer: the Italian, multicenter, observational PANCAKE study. Last author DOI 10.1016/j.esmogo.2025.100276↗
  3. Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection. Co-author DOI 10.1093/oncolo/oyag085↗
  4. Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants. Co-author DOI 10.1002/cam4.70364↗
  5. A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemothe… Last author DOI 10.1016/j.dld.2025.11.007↗
  6. Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine-nab-paclitaxel failure: a propensity score… Co-author DOI 10.1016/j.esmoop.2025.105874↗
  7. NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis. Last author DOI 10.1001/jamanetworkopen.2023.50756↗
  8. Molecular Characterization and Clinical Relevance of MGMT-Silenced Pancreatic Cancer. Last author DOI 10.1002/cam4.70393↗
  9. Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA… Co-author DOI 10.1007/s00280-023-04585-w↗
  10. Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort. Co-author DOI 10.1016/j.ejca.2023.04.012↗
  11. Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.01.016↗
  12. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv). Co-author DOI 10.1038/s41416-022-02086-w↗
  13. Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. Co-author DOI 10.1016/j.esmoop.2020.100032↗
  14. Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter surve… Co-author DOI 10.1016/j.esmoop.2021.100238↗
  15. Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and … Co-author DOI 10.3390/cancers11040484↗

Closest collaborators

The 25 strongest of 75 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Giampaolo Tortora · 8 shared papers, 2021–2026 · strength 1.19
  2. Lisa Salvatore · 7 shared papers, 2021–2026 · strength 1.06
  3. Federico Nichetti · 6 shared papers, 2019–2026 · strength 0.97
  4. Mario Scartozzi · 6 shared papers, 2021–2026 · strength 0.96
  5. Caterina Vivaldi · 5 shared papers, 2023–2026 · strength 0.89
  6. Elisa Giommoni · 6 shared papers, 2021–2026 · strength 0.87
  7. Letizia Procaccio · 5 shared papers, 2023–2026 · strength 0.81
  8. Guido Giordano · 6 shared papers, 2021–2026 · strength 0.80
  9. Ilario Giovanni Rapposelli · 6 shared papers, 2021–2025 · strength 0.76
  10. Silvia Bozzarelli · 5 shared papers, 2021–2025 · strength 0.67
  11. Carolina Sciortino · 3 shared papers, 2025–2026 · strength 0.67
  12. Mariacristina Di Marco · 5 shared papers, 2021–2026 · strength 0.66
  13. Sara Lonardi · 4 shared papers, 2023–2026 · strength 0.62
  14. Marina Macchini · 5 shared papers, 2021–2025 · strength 0.60
  15. Giulia Orsi · 5 shared papers, 2021–2025 · strength 0.60
  16. Michèle Milella · 5 shared papers, 2021–2025 · strength 0.60
  17. Michele Reni · 5 shared papers, 2021–2025 · strength 0.60
  18. Stefano Cascinu · 5 shared papers, 2021–2025 · strength 0.60
  19. Andrea Pretta · 3 shared papers, 2025–2026 · strength 0.59
  20. Vincenzo Mazzaferro · 3 shared papers, 2024–2026 · strength 0.54
  21. Ingrid Garajová · 4 shared papers, 2021–2025 · strength 0.53
  22. Francesca Bergamo · 3 shared papers, 2025–2026 · strength 0.52
  23. Enrico Vasile · 3 shared papers, 2023–2026 · strength 0.48
  24. Maria Grazia Rodriquenz · 4 shared papers, 2021–2025 · strength 0.46
  25. Christoph Benedikt Westphalen · 2 shared papers, 2023–2026 · strength 0.44

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.